Laekna Showcases Novel Oral Obesity Candidate LAE124
Shanghai, China, November 11, 2026 Laekna Inc. has announced that its internally discovered investigational drug candidate LAE124, a novel...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Shanghai, China, November 11, 2026 Laekna Inc. has announced that its internally discovered investigational drug candidate LAE124, a novel...
Oxford, England, United Kingdom, November 11, 2026 Caristo Diagnostics has announced the publication of a major clinical research study...
Shanghai, China, and Hong Kong, November 11, 2026 Antengene Corporation Limited has presented new preclinical findings for ATG-207, an...
San Francisco, California, U.S., November 11, 2026 Skribe Medical has announced significant progress in developing its Aurora wearable cardiac...
Orlando, Florida, U.S., November 11, 2026 The Lupus Research Alliance (LRA) has awarded its prestigious 2026 Lupus Insight Prize...
Singapore and Princeton, New Jersey, U.S., November 11, 2026 Shanton Pharma has announced that it has secured important regulatory...
Abbott Park, Illinois, U.S., November 10, 2026 Abbott, a global healthcare company, has announced that it has received U.S....
Emeryville, California, U.S., November 10, 2026 Metagenomi Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA)...
Stamford, Connecticut, U.S., November 11, 2026 Beeline Medicines Corporation has announced positive detailed results from its global Phase 2...
Boston, Massachusetts, U.S., November 10, 2026 Nimbus Therapeutics has announced the first-in-human dosing of NDI-225673, an investigational, highly selective...
